Premier Integrated Platform in APAC to Develop Innovative Therapies for Oncology Antengene Corporation Limited Successfully Listed on Main Board of SEHK
HONG KONG, Nov 20, 2020 - (ACN Newswire) - Antengene Corporation Limited ("Antengene" or the "Company", together with its subsidiaries, the "Group", stock code: 6996.HK), a clinical-stage biopharmaceutical company with integrated drug discovery, clinical development, anchored in Asia-Pacific (APAC) with a global layout, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.Antengene's listing ceremony in Shanghai: Dr. Jay Mei, M.D., Ph.D., founder, Chairman and CEO (Left); Mr. Yiteng Liu, M.Sc., Chief Operating Officer (Right) The total number of offer shares under the Global Offering amounts to 154,153,500 shares, with the final offer price determined at HK$18.08 per offer share. The net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and expenses paid and payable by the Company in connection with the Global Offering, are estimated to be approximately HK$2,635.9 million. The Hong Kong offer shares initially offered under the Hong Kong Public Offering have received satisfactory response, where the total number of valid applications amounted to approximately 264...
